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Background
• Desmoid tumor represents an intermediate grade neoplasm with a
striking predilection for locally invasive growth and recurrence
following resection
• More effective, well-tolerated non-surgical treatment options are
needed
• Current approaches
• If feasible, watchful waiting is the preferred approach
• 20-30% spontaneous regression
• In situations where treatment is indicated, the following
approaches are utilized
• Surgery is the primary approach if minimal morbidity is
anticipated
• Medical therapies
• Cytotoxic drugs
• Tyrosine kinase inhibitors
• Hydroxyurea
• Gamma secretase inhibitors
• mTOR Inhibitor Rationale
• Desmoid tumor is well-known to be associated with
deregulation of the APC/β-catenin pathway
• Deregulation of the mTOR cell proliferation/survival pathway
may play an important role in tumor biology when the APC/βcatenin pathway is disrupted
• The mTOR inhibitor sirolimus is attractive as a potential targeted
therapy for desmoid tumor
• Well-tolerated in children and young adults
• Can be given orally in tablet or liquid formulation

Methods
• Multi-institutional study open and actively accruing patients
• Eligibility criteria
• <30 years of age
• Surgery is planned to remove their desmoid tumor and either
• (a) the desmoid tumor has already recurred after a prior
surgery or
• (b) the newly diagnosed or previously unresected disease is
judged to be at high risk for recurrence due to its size (>5 cm)
or location at an anatomic site making it unlikely to be
resected with negative margins (e.g., adjacent to
neurovascular structures)
• Patients with germline APC causing FAP/Gardner’s syndrome
• This is an IRB-approved study and patient consent is required

• Tissue
• Pre-therapy biopsy
• Post-therapy biopsy
• Archived specimens (future analysis)
•
Paired, pre-treatment
•
Non-chemotherapy treatment
Figure 2. Representative pre- and post-operative IHC staining for mTOR
pathway proteins p4E-BP1, p70S6K, and pAKT in desmoid tumor
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Figure 1. Experimental Design Schema
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Objectives
• Primary
1. To determine whether mTOR pathway activation decreases in
patients with surgically resectable desmoid tumor that is
removed following pre-operative treatment with sirolimus
• Secondary
1. To assess whether sirolimus improves desmoid tumor-associated
pain
2. To begin to explore whether pre-operative sirolimus decreases
tumor recurrence following surgical removal of desmoid tumor
felt to be at high-risk for recurrence because of size and/or
anatomic site
3. To assess the safety and tolerability of pre-operative sirolimus in
patients with desmoid tumor

Histologic Assessment

Results
• Nine of an anticipated 15 total patients have enrolled to date
• Ages have ranged from 5 to 28 years
• All patients have been able to take the pre-operative sirolimus as
prescribed and undergone surgery within the protocol-directed time
frame
• All toxicities have been as expected and Common Terminology
Criteria for Adverse Events grade 1 and 2 only except for one grade 3
neutropenia
• No post-operative complications have been reported
• IHC staining is ongoing for p4E-BP1, p70S6K, and pAKT (Figure 2)
• Pain assessment measurements and anatomical imaging are being
performed at designated surveillance intervals

Conclusion
• Sirolimus appears to be well-tolerated when administered in the preoperative setting to children and young adults with desmoid tumor
• Surgery is feasible and safe immediately after completing therapy
• Formal assessment of the mTOR pathway by IHC analysis will take
place at study completion
• The study continues to actively accrue
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